

Eco-architecting the drug lifecycle: Green engineering and circular design in modern pharmaceuticals



Binu Raina^{1*}, Abhimanyu², Ashwani Kumar Dhingra³, Sakshi Bajaj³

¹Guru Gobind Singh College of Pharmacy, Yamuna Nagar, Haryana, India.

²Chaudhary Devi Lal College of Pharmacy, Yamuna Nagar, Haryana, India.

³Global Research Institute of Pharmacy, Yamuna Nagar, Haryana, India.

Email: binuraina407@gmail.com

Abstract

The pharmaceutical business is under unprecedented pressure to reduce its environmental impact while upholding strict requirements for product efficacy, safety, and quality. This article traces the lifecycle of a drug product from green molecule design through eco-friendly manufacturing and packaging to responsible disposal, examining the paradigm change toward sustainable pharmaceutical technologies. The industry may move toward a net-zero future by incorporating Green Chemistry concepts, cutting-edge engineering like continuous manufacturing, biodegradable packaging materials, and circular economy waste management techniques.

Keywords: Sustainable Pharmaceutical Technology, Green Chemistry, Continuous Manufacturing

1. Introduction

Although the global pharmaceutical industry is vital to human healthcare, its waste streams and manufacturing supply chains greatly worsen environmental conditions. Conventional batch manufacturing methods use a lot of resources and frequently produce large amounts of toxic organic waste, high carbon emissions, and packaging materials that are not biodegradable. Additionally, an increasing ecotoxicological hazard is posed by the ongoing introduction of Active Pharmaceutical Ingredients (APIs) into aquatic ecosystems through production effluents and inappropriate disposal, which is accelerated by the increase of Antimicrobial Resistance (AMR) (1).

The idea of "Sustainability by Design" (SbD) (Figure 1) has arisen as a guiding framework to solve these issues. From the very beginning of medication development to the final phases of patient use and disposal, this method requires that the effects on the environment, human health, and safety be assessed alongside therapeutic efficacy. Three main pillars must be

completely transformed in order to achieve sustainable pharmacy: green synthesis, eco-efficient manufacturing technologies, and circular packaging solutions.




Figure 1. Sustainability by Design approach in drug lifecycle

2. Green Chemistry and Sustainable Process Design

The pursuit of sustainable pharmaceutical technology commences at the molecular level. Historically, the synthesis of intricate active pharmaceutical ingredients has depended on multi-step organic processes employing toxic solvents, heavy metal catalysts, and energy-intensive heat conditions. The concept of Green Chemistry formulated by Anastas and Warner, has been introduced in order to minimize the environmental impact (2, 3).

The Environmental Factor (E-factor), which quantifies the waste produced per kilogram of intended output, is a very important indicator employed to assess efficiency (4). A value closer to zero (E-Factor ~ 0) indicates less waste generation and a more sustainable and greener process (5). Traditional pharmaceutical manufacturing often has E-factors ranging from 25 to 100, indicating a significant waste imbalance, whereas oil refining has an E-factor near zero (6). Modern technologies based on sustainability focus to lower this ratio through several approaches:

- **Biocatalysis and Enzyme Engineering**

Substituting highly precise, designed enzymes for dangerous heavy metal catalysts like palladium or platinum is preferred so that reactions could occur at mild, ambient settings in aqueous environments. Energy use and hazardous secondary waste production are significantly reduced as a result (7).

- **Solvent Selection and Recovery**

Economical recycling strategies can be improved by effective solvent selection and recovery. Volatile Organic Compounds (VOCs) used in typical batch processes generally comprise 80% of the non-API mass. Sustainable manufacturing is possible by prioritizing bio-derived or "green" solvents (e.g., ethyl lactate, 2-methyltetrahydrofuran) and implementing closed-loop solvent recovery systems to recycle media directly back into the production cycle (8).

3. Advanced Manufacturing Technologies

Transformation from conventional batch processing to advanced engineering paradigms is a cornerstone of industrial sustainability.

3.1 Continuous Manufacturing (CM)

Continuous Manufacturing (CM) signifies a significant shift away from conventional batch processing methods. Within a CM configuration, raw materials are consistently introduced into a cohesive system that carries out synthesis, purification, blending, and tableting in one seamless, ongoing process (9).

The sustainability advantages of CM over batch processing are extensive, as detailed in Table 1.

Table 1. Comparative Sustainability Matrix of Batch vs. Continuous Manufacturing.

Parameter	Traditional Batch Manufacturing	Continuous Manufacturing (CM)	Sustainability Impact
Equipment Footprint	Large facilities, massive holding tanks	Compact, integrated modular units	Up to 70% reduction in facility footprint, lowering HVAC energy loads.
Material Waste	High; entire batches discarded if deviations occur	Minimal; out-of-specification material rejected instantly	Significant reduction in raw material consumption and scrap waste.
Solvent/Water Use	Extensive cleaning validation between batches	Long production runs minimize cleaning frequency	Lower water-for-injection (WFI) usage and reduced chemical detergent waste.

3.2 Process Analytical Technology (PAT)

Utilizing Process Analytical Technology (PAT) tools, like Near-Infrared (NIR) and Raman spectroscopy, enables ongoing, non-intrusive monitoring of critical quality attributes during manufacturing. The capability of PAT to identify process deviations aids in preventing the creation of defective sub-batches, thereby minimizing the considerable energy and material waste associated with reprocessing or discarding unsuccessful batches (10). Below are given some of the examples:

- **Moisture and Particle Growth (NIR):** Simultaneous determination of some characteristics like moisture content, bulk density, and particle size distribution in fluidized bed granulators using multi-wavelength/diffuse reflectance sensors through glass sight windows.
- **Polymer-Drug Interactions (Raman):** Using die-mounted contact probes, in-line monitoring of continuous hot-melt extrusion (HME) is used to measure API concentration and distinguish between solid solutions and solid dispersions using Raman peak shifts and band broadening.
- **Active Coating Quantitation (Raman):** Using non-contact optics shielded by pressured air purges, in-line tracking of API deposition and process endpoint determination during active pan coating is done.

4. Eco-Friendly Packaging Technologies

Every product has its shelf life. To ensure the safety of a product during its shelf-life period is possible only if we protect it appropriately with proper packaging. The pharmaceutical product might degrade under a number of unfavourable conditions like oxygen, light, moisture etc. To address this, multi-layer plastic blister packs laminated with polyvinyl chloride (PVC) and aluminium foil remain common in practice. These composite materials are hard to recycle, so they are mainly disposed of in landfills or incinerated.

4.1 Bio-Based and Biodegradable Polymers

Innovations in material science have recently introduced sustainable options that align with strict regulatory standards.:

- **Polylactic Acid (PLA):** PLA is a plant-based polyester obtained from renewable agricultural resources like sugarcane and corn starch. It is produced by fermenting plant starches into lactic acid and then polymerised into raw plastic resin. It is often used for non-sterile device components and secondary packaging to rely minimally on polymers originating from fossil fuels (11).
- **Polyhydroxyalkanoates (PHAs):** These biodegradable polymers are fermented microbially and have proven to be superior moisture barriers which are completely biodegradable in soil and marine settings. At the industrial level these polymers have been widely used for making water resistance surface over paper and cardboard, food packaging, and plastic beverage bottles (12).

4.2 Mono-Material Blister Packs

To overcome the recycling limitations of composite blisters, the industry is shifting towards designs that use a single material. There are more sustainable alternatives to conventional pharmaceutical packaging, like the utilization of waterproof paper enhanced with nanoclay and starch and a modified PVC alternative to costly PVDC. With sustainability as a key factor, the entire blister pack is structured to be recyclable within standard household recycling systems. This has been made possible by using mono-materials such as high-density polyethylene (HDPE) or polypropylene (PP), which have been enhanced with particular barrier coatings, thus removing the necessity to mechanically separate the foil from the plastic (13).

5. End-of-Life Management: From Facility to Disposal

A truly sustainable pharmaceutical lifecycle must address the fate of chemical compounds and packaging materials after they leave the manufacturing floor.

5.1 Mitigation of Active Pharmaceutical Ingredients in the Environment (PIE)

The contamination of waterways by APIs via discharge from pharmaceutical manufacturing and patient excretion is an evolving global crisis. Actions have been taken like destruction of active metabolites at the manufacturing site before discharge, to lower the risk caused by discharge:

- **Advanced Oxidation Processes (AOPs):** AOPs serve as an efficient treatment strategy where other standard biological and physical treatments fail because of low pollutant biodegradability. Chemical and irradiation-driven techniques—such as ozonation, photo-Fenton reactions, radical-based UV systems, electrochemical oxidation, and

sonolysis produce reactive oxidative radicals through decomposition of ozone, iron-peroxide reactions, oxidant activation, and sonic cavitation (14).

- **Membrane Bioreactors (MBRs):** Biological degradation of organic matter is integrated with membrane filtration (microfiltration/ultrafiltration) more efficiently than traditional wastewater treatment facilities. MBR systems reinforce the growth of specialized, slow-growing, and dispersed bacteria along with standard floc-forming microorganisms. This process plays a significant role in Enhanced Contaminant Elimination (Pravastatin, mefenamic acid, indomethacin, diclofenac, achieving higher biodegradation rates in the aqueous phase), Superior Effluent Quality (lower chemical oxygen demand, lower biological oxygen demand, and effective ammonia removal), and Reduced Sludge Contamination & Cost (15).

5.2 Extended Producer Responsibility (EPR) and Circular Economy

Pharmaceutical businesses are embracing Extended Producer Responsibility (EPR) with a target to minimize waste at the patient level. Instead of being drained down the toilet or dumped in municipal landfills, these architectures create institutional take-back programs that assures that untapped or expired medications are assembled and burned in high-temperature, clean-emissions facilities with high energy recovery systems (16, 17).

6. Conclusion

From molecular design to end-of-life disposal, the shift to sustainable pharmaceutical technologies necessitates an integrated commitment. The pharmaceutical sector can attain ecological neutrality without sacrificing patient safety by implementing Green Chemistry, switching to continuous manufacturing paradigms, developing mono-material packaging, and protecting waste streams from environmental leakage. Adopting this cutting-edge technology is now an ethical requirement to safeguard the environment and public health worldwide, rather than just a way to comply with regulations.

Transitioning from molecular design to end of life, environmental sustainability requires a systemic lifecycle shift guided by the "Sustainability by Design" (SbD) structure, aligning product efficacy and safety with ecological responsibility. Accomplishing this balance depends on integrating green chemistry—like biocatalysis and renewable solvents to lower high E-factors—with continuous manufacturing and Process Analytical Technology (PAT) to reduce energy, water, and material waste. Concurrently, switching to recyclable mono-materials and bio-based polymers eradicates downstream packaging burdens, while advanced effluent treatments (AOPs and MBRs) alongside Extended Producer Responsibility (EPR) approaches prevent aquatic contamination. Ultimately, realizing a net-zero pharmaceutical sector necessitates multi-stakeholder collaboration across chemistry, regulation and engineering, ensuring that safeguarding human health does not challenge environmental integrity.

7. References

1. Kummerer K. Antibiotics in the environment—a review. *Chemosphere*. 2009;75(4):417-434.
2. Anastas PT, Warner JC. *Green Chemistry: Theory and Practice*. Oxford University Press; 1998.
3. Chen TL, Kim H, Pan SY, Tseng PC, Lin YP, Chiang PC. Implementation of green chemistry principles in circular economy system towards sustainable development goals: Challenges and perspectives. *Sci Total Environ*. 2020;716
4. Sheldon RA, Bode ML, Akakios SG. Metrics of green chemistry: Waste minimization. *Curr Opin Green Ind Chem*. 2022;33

5. Tobiszewski M, Marc M, Gałuszka A, Namiesnik J. Green Chemistry Metrics with Special Reference to Green Analytical Chemistry. *Molecules*. 2015;20(6):10928-10946.
6. Sheldon RA. The E Factor 25 years on: the rise of green chemistry and sustainability. *Green Chemistry*. 2017;19(1):18-43.
7. Farhan M, Hasani IW, Khafaga DSR, Ragab WM, Kazi RNA, Aatif M, et al. Enzymes as catalysts in industrial biocatalysis: advances in engineering, applications, and sustainable integration. *Catalysts*. 2025;15(9):891.
8. Constable DJ, Jimenez-Gonzalez C, Henderson RK. Perspective on solvent use in the pharmaceutical industry. *Organic Process Research & Development*. 2007;11(1):133-137.
9. Alemie AA, Siraj EA, Yayehrad AT, Tafere C, Tessema TA, Belete A. Continuous pharmaceutical manufacturing and its contemporary regulatory insights. *Discover Appl Sci*. 2025;7:1057.
10. Bakeev KA, ed. *Process Analytical Technology: Spectroscopic Tools and Implementation Strategies for Pharmaceutical Processes*. 2nd ed. John Wiley & Sons; 2010.
11. Zhao X, Wang Y, Chen X, Yu X, Li W, Zhang S, Meng X, Zhao ZM, Dong T, Anderson A, Aiyedun A, Li Y, Webb E, Wu Z, Kunc V, Ragauskas A, Ozcan S, Zhu H. Sustainable bioplastics derived from renewable natural resources for food packaging. *Matter*. 2023 Jan 4;6(1):97-127.
12. Philip S, Keshavarz T, Roy I. Polyhydroxyalkanoates: biodegradable polymers with a range of applications. *Journal of Chemical Technology & Biotechnology*. 2007;82(3):233-247.
13. Pedrosa D, Costa J, Oliveira L. Sustainability of blisters for medicines in tablet form. *Sustain Chem Pharm*. 2021;21.
14. Covinich LG, Bengoechea DI, Fenoglio RJ, Area MC. Advanced oxidation processes for wastewater treatment in the pulp and paper industry: A review. *Am J Environ Eng*. 2014;4(3):56-70.
15. Radjenovic J, Petrovic M, Barcelo D. Fate and distribution of pharmaceuticals in wastewater and sewage sludge of the conventional activated sludge (CAS) and advanced membrane bioreactor (MBR) treatment. *Water Research*. 2009;43(3):831-841.
16. Abu-Qdais H, Al-Saleh M. Developing an extended producer responsibility system for solid waste management in Jordan using multi-criteria decision-making approach. *Waste Manag Res*. 2024 Jul;42(7):533-543
17. Mayanti B, Helo P. Circular economy through waste reverse logistics under extended producer responsibility in Finland. *Waste Manag Res*. 2024 Jan;42(1):59-73.